Comparative Pharmacology
Head-to-head clinical analysis: NITROFURANTOIN versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROFURANTOIN versus XERAVA.
NITROFURANTOIN vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inactivate or inhibit bacterial ribosomal proteins, DNA, RNA, and metabolic enzymes, leading to bacterial cell death.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
100 mg orally twice daily for 5-7 days (uncomplicated UTI); 50-100 mg orally four times daily for 7 days (symptomatic uncomplicated UTI). Extended-release: 100 mg orally twice daily for 7 days.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
Clinical Note
moderateNitrofurantoin + Norfloxacin
"The therapeutic efficacy of Norfloxacin can be decreased when used in combination with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Rolapitant
Normal renal function: 20-60 minutes; impaired function: prolonged up to 1-2 hours, clinically significant due to urinary concentration requirement
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Renal: ~40% unchanged via glomerular filtration and tubular secretion, biliary/fecal: <1%
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category D/X
Category C
Antibiotic
Antibiotic
"The serum concentration of Rolapitant can be increased when it is combined with Nitrofurantoin."